Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
Koevoets EW, Schagen SB, de Ruiter MB, Geerlings MI, Witlox L, van der Wall E, Stuiver MM, Sonke GS, Velthuis MJ, Jobsen JJ, Menke-Pluijmers MBE, Göker E, van der Pol CC, Bos MEMM, Tick LW, van Holsteijn NA, van der Palen J, May AM, Monninkhof EM; PAM study group. Koevoets EW, et al. Among authors: goker e. Breast Cancer Res. 2022 May 26;24(1):36. doi: 10.1186/s13058-022-01530-2. Breast Cancer Res. 2022. PMID: 35619188 Free PMC article. Clinical Trial.
The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients.
Gregorowitsch ML, Ghedri A, Young-Afat DA, Bijlsma R, Baas IO, van Schaik-van de Mheen C, Agterof MJ, Göker E, Ten Bokkel Huinink D, van den Bongard HJGD, Verkooijen HM; UMBRELLA study group. Gregorowitsch ML, et al. Among authors: goker e. Breast Cancer Res Treat. 2019 Jun;175(2):429-441. doi: 10.1007/s10549-019-05149-4. Epub 2019 Feb 12. Breast Cancer Res Treat. 2019. PMID: 30746636 Free PMC article.
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Göker E, Hendriks MP, van Tilburg M, Barcaru A, Mittempergher L, van Egmond A, Kleijn M, Generali D; of the NBREaST II Investigators Group. Göker E, et al. Eur J Cancer. 2022 May;167:92-102. doi: 10.1016/j.ejca.2022.03.003. Epub 2022 Apr 11. Eur J Cancer. 2022. PMID: 35421703 Free article.
Effect of physical exercise on the hippocampus and global grey matter volume in breast cancer patients: A randomized controlled trial (PAM study).
Koevoets EW, Geerlings MI, Monninkhof EM, Mandl R, Witlox L, van der Wall E, Stuiver MM, Sonke GS, Velthuis MJ, Jobsen JJ, van der Palen J, Bos MEMM, Göker E, Menke-Pluijmers MBE, Sommeijer DW, May AM, de Ruiter MB, Schagen SB; PAM study group. Koevoets EW, et al. Among authors: goker e. Neuroimage Clin. 2023;37:103292. doi: 10.1016/j.nicl.2022.103292. Epub 2022 Dec 14. Neuroimage Clin. 2023. PMID: 36565574 Free PMC article. Clinical Trial.
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.
de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, Smit VTHBM, de Graaf H, Heijns JB, Portielje JEA, van de Wouw AJ, Imholz ALT, Kessels LW, Vrijaldenhoven S, Baars A, Kranenbarg EM, Carpentier MD, Putter H, van der Hoeven JJM, Nortier JWR, Longo VD, Pijl H, Kroep JR; Dutch Breast Cancer Research Group (BOOG). de Groot S, et al. Nat Commun. 2020 Jun 23;11(1):3083. doi: 10.1038/s41467-020-16138-3. Nat Commun. 2020. PMID: 32576828 Free PMC article. Clinical Trial.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival?
Güzel D, Terek C, Besler A, Serin G, Önal Z, Akman L, Göker E, Ali Şanli U, Zekioğlu O, Özdemir N, Özsaran A, Yildirim N. Güzel D, et al. Among authors: goker e. Eur J Obstet Gynecol Reprod Biol. 2024 May;296:321-326. doi: 10.1016/j.ejogrb.2024.03.021. Epub 2024 Mar 18. Eur J Obstet Gynecol Reprod Biol. 2024. PMID: 38518487
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey.
Akyildiz A, Guven DC, Ozluk AA, Ismayilov R, Mutlu E, Unal OU, Yildiz I, Iriagac Y, Turhal S, Akbas S, Bayram E, Telli TA, Turkoz FP, Ozcelik M, Erciyestepe M, Selvi O, Gulbagci B, Erturk I, Isleyen ZS, Kahraman S, Akdag MO, Hamitoglu B, Unek IT, Unal C, Hacibekiroglu İ, Arslan C, Azizy A, Helvaci K, Demirci U, Dizdar O, Basaran M, Goker E, Sendur MA, Yalcin S. Akyildiz A, et al. Among authors: goker e. Medicine (Baltimore). 2023 Nov 10;102(45):e35950. doi: 10.1097/MD.0000000000035950. Medicine (Baltimore). 2023. PMID: 37960746 Free PMC article.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
116 results